Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. MiMedx Group, Inc.
WARNING LETTER
•MiMedx Group, Inc.•March 2, 2023

MiMedx Group, Inc. – FDA Warning Letter, Mar 2, 2023

Record Details

The FDA issued a Warning Letter to MiMedx Group, Inc. on December 20, 2023, following inspections from February 22 to March 2, 2023, at their Kennesaw and Marietta, GA facilities. The inspections documented the manufacture and distribution of AXIOFILL™ (Placental Collagen Matrix), a placenta-derived product intended for topical application to wounds.

The FDA determined AXIOFILL™ is an unapproved new drug and biological product, as it fails to meet the minimal manipulation criterion for HCT/Ps (21 CFR 1271.10(a)(1)) and is not solely regulated under 21 CFR Part 1271. It lacks an approved Biologics License Application (BLA) or an Investigational New Drug (IND) application, violating the FD&C Act and PHS Act.

Furthermore, the inspection revealed significant deviations from Current Good Manufacturing Practice (CGMP) requirements (21 CFR Parts 210 and 211), including: 1. Failure to establish adequate written procedures for production and process control to assure product identity, strength, purity, and quality (21 CFR 211.100(a)). 2. Failure to establish laboratory controls with scientifically sound and appropriate specifications for identity, strength, quality, and purity (21 CFR 211.160(b)).

Company
MiMedx Group, Inc.
Inspection date
March 2, 2023
Product type
Biologics
Office
Center for Biologics Evaluation and Research
Person
  • Michael W. Roosevelt (Program Division Director)
View Company Profile

ID · a3e8fe0c-5d5b-450b-820f-3c8e6d7fd532

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 U.S.C. 321(g)(1)(B)21 CFR 1271.3(d)21 CFR 127121 CFR 1271.10(a)21 CFR 1271.10(a)(1)21 CFR 1271.3(f)(1)21 CFR 201.32142 U.S.C. 262(a)21 U.S.C. 355(i)

Full citation text and observation details available on the Dashboard.

Other documents for MiMedx Group, Inc.
  • 483 - 2023-03-02March 2, 2023
  • 483 - 2019-12-12December 12, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore MiMedx Group, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.